Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

AACR 2025 | MYTHIC: lunresertib and camonsertib in ovarian and endometrial cancers

Alison Schram • 28 Apr 2025
AACR 2025
Endometrial Cancer Gynecological Cancer Ovarian Cancer Camonsertib Lunresertib
MYTHIC

Alison Schram, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the Phase I MYTHIC study (NCT04855656) of lunresertib, a PKMYT1 inhibitor, with camonsertib, an ATR inhibitor, in patients with ovarian and endometrial cancers. The regimen was generally well tolerated, with manageable hematologic toxicity. Clinical and molecular responses, including tumor shrinkage and ctDNA reduction, support further development in biomarker-selected populations with limited treatment options. This interview took place at American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Alison Schram

NRG1 fusion-positive tumors and real-world insights in PDAC
8:56
NRG1 fusion-positive tumors and real-world insights in PDAC
Alison Schram • 28 Apr 2025
Characterizing TP53 Y220C mutations across solid tumors
5:23
Characterizing TP53 Y220C mutations across solid tumors
Alison Schram • 28 Apr 2025
eNRGy: zenocutuzumab in NRG1 fusion-positive pancreatic ductal adenocarcinoma
0:46
eNRGy: zenocutuzumab in NRG1 fusion-positive pancreatic ductal adenocarcinoma
Alison Schram • 21 Oct 2023
eNRGy: zenocutuzumab in NRG1 fusion-positive NSCLC
1:56
eNRGy: zenocutuzumab in NRG1 fusion-positive NSCLC
Alison Schram • 21 Oct 2023

Related Videos

The future of antibody-drug conjugates in endometrial cancer
1:10
The future of antibody-drug conjugates in endometrial cancer
Linda Mileshkin • 30 May 2026
B7-H4-directed ADC in endometrial versus ovarian cancer
0:43
B7-H4-directed ADC in endometrial versus ovarian cancer
Linda Mileshkin • 30 May 2026
Barriers to cervical cancer screening among rural women in India
0:54
Barriers to cervical cancer screening among rural women in India
Shailendra Dandge • 31 May 2026
A community-based model for cervical cancer screening uptake in rural India
8:39
A community-based model for cervical cancer screening uptake in rural India
Shailendra Dandge • 31 May 2026
The content of VJOncology is intended for healthcare professionals